Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Randomized Study of Isolated Limb Perfusion Using Melphalan With or Without Tumor Necrosis Factor in Patients With Unresectable High Grade Soft Tissue Sarcomas of the Extremity

NCT00019968 is registered in ClinicalTrials.gov with National Institutes of Health Clinical Center (CC) as lead sponsor.

NCT NCT00019968
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00019968 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Randomized Study of Isolated Limb Perfusion Using Melphalan With or Without Tumor Necrosis Factor in Patients With Unresectable High Grade Soft Tissue Sarcomas of the Extremity
Lead sponsor
National Institutes of Health Clinical Center (CC)
Phase
Phase 2
Overall status
Completed
Start date
August 31, 1999
Completion date
March 31, 2002
Enrollment
Not reported
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent adult soft tissue sarcoma, stage iib adult soft tissue sarcoma, stage iic adult soft tissue sarcoma, stage iii adult soft tissue sarcoma, stage iva adult soft tissue sarcoma, stage ivb adult soft tissue sarcoma